Condition: Hepatocellular Carcinoma · Sponsor: University Hospital, Rouen
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.
This description comes directly from the study's public registry record.
Edouard ROUSSEL, MD · +3323288 · edouard.roussel@chu-rouen.fr
Julie RONDEAUX · +3323288 · julie.rondeaux@chu-rouen.fr
Always discuss trial participation with your own doctor first.
| Chu Rouen | Rouen, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05375370